Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

ClinicalTrials.gov ID: NCT01521598

Public ClinicalTrials.gov record NCT01521598. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 16, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study Assessing the Efficacy and Tolerability of SKL11197 for the Pain of Diabetic Peripheral Neuropathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: To evaluate the efficacy of SKL11197 for the treatment of diabetic peripheral neuropathy pain (DPN). Secondary Objective: To evaluate the safety and tolerability of SKL11197 in subjects with painful diabetic peripheral neuropathy. Primary Efficacy Endpoint: The primary efficacy outcome variable will be the time to exit from the double-blind phase because of inadequate pain relief.

Study identification

NCT ID
NCT01521598
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
SK Life Science, Inc.
Industry
Enrollment
128 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2011
Primary completion
May 31, 2013
Completion
May 31, 2013
Last update posted
Jun 10, 2015

2012 – 2013

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Neurology Clinic, P.C. Northport Alabama 35476
Principals Research Group Hot Springs Arkansas 71901
Clinical Trials, Inc. Little Rock Arkansas 72205
Collaborative Neuroscience Network, Inc. Long Beach California 90806
Neurological Research Institute Santa Monica California 90404
Renstar Medical Research Ocala Florida 33471
Comprehensive Clinical Development St. Petersburg Florida 33716
Clinical Research of West Florida, Inc. Tampa Florida 33603
International Clinical Research Institute Leawood Kansas 66211
Michigan Head Pain & Neurological Institute. Ann Arbor Michigan 48104
Creighton Diabetes Center Omaha Nebraska 68131
Sunstone Medical Research, LLC Medford Oregon 97504
Nerve and Muscle Center of Texas Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01521598, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 10, 2015 · Synced Sep 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01521598 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →